Sona Nanotech Inc. Share Price

Equities

SONA

CA83541C1059

Medical Equipment, Supplies & Distribution

Market Closed - Canadian Securities Exchange 01:24:55 30/04/2024 am IST 5-day change 1st Jan Change
0.35 CAD 0.00% Intraday chart for Sona Nanotech Inc. -16.67% +45.83%

Financials

Sales 2022 - Sales 2023 - Capitalization 16.64M 22.79M 1.39B
Net income 2022 -2M -2.74M -167M Net income 2023 -2M -2.74M -167M EV / Sales 2022 -
Net Debt 2022 444K 608K 37.08M Net Debt 2023 412K 565K 34.43M EV / Sales 2023 -
P/E ratio 2022
-4.2 x
P/E ratio 2023
-6 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 84.54%
More Fundamentals * Assessed data
Dynamic Chart
1 week-16.67%
Current month-22.22%
1 month-22.22%
3 months+25.00%
6 months+100.00%
Current year+45.83%
More quotes
1 week
0.35
Extreme 0.345
0.42
1 month
0.33
Extreme 0.33
0.56
Current year
0.24
Extreme 0.24
0.56
1 year
0.14
Extreme 0.135
0.56
3 years
0.02
Extreme 0.02
1.82
5 years
0.01
Extreme 0.01
16.05
10 years
0.00
Extreme 0
16.05
More quotes
Managers TitleAgeSince
Founder - 17/04/17
Founder - 17/04/17
Chief Executive Officer 55 07/20/07
Members of the board TitleAgeSince
Chairman - 03/20/03
Director/Board Member - 04/22/04
Director/Board Member 59 19/19/19
More insiders
Date Price Change Volume
29/24/29 0.35 -14.63% 120,130
26/24/26 0.41 -2.38% 2,214
25/24/25 0.42 +5.00% 22,525
24/24/24 0.4 -4.76% 28,225
23/24/23 0.42 0.00% 11,000

Delayed Quote Canadian Securities Exchange, April 30, 2024 at 01:24 am IST

More quotes
Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for the manufacturing of various types of gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company leverages its core proprietary gold nanorod (GNR) manufacturing technology and laboratory assets to focus on the development of diagnostic tests and biologic reagents, and the advancement of its GNR intellectual property.
More about the company